Business
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights
WALTHAM, Mass., October 29, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/ac65d6aa1c5bb5b9516b0e68c1f2b972"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Aok12P1VtAdcEp.2nNj0jQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ac65d6aa1c5bb5b9516b0e68c1f2b972","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NC3x3Vk0UftiBruxX7XvwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ac65d6aa1c5bb5b9516b0e68c1f2b972","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies - reflecting the company’s disciplined approach to capital deployment","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., October 29, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.","length":492,"tagName":"p"},{"type":"text","content":"Clario integrates clinical trial endpoint data from devices, sites and patients enabling pharma and biotech customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions. The company’s platform has supported approximately 70% of FDA drug approvals over the past decade.","length":366,"tagName":"p"},{"type":"text","content":"Clinical trial endpoint data refers to the specifi...